Jung Hun Kang

Jung Hun Kang

Auto-generated profile, based on publicly available information

Jung Hun Kang

Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, South Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
JKJung Hun Kang
Jung Hun Kang
DHDavid Hui
David Hui
MKMoon Jin Kim
Moon Jin Kim
HKHoon Gu Kim
Hoon Gu Kim
MKMyoung Hee Kang
Myoung Hee Kang
EBEduardo Bruera
Eduardo Bruera

8 October 2009 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
GLGyeong-Won Lee
Gyeong-Won Lee
JKJung-Hun Kang
Jung-Hun Kang
IKIn-Suk Kim
In-Suk Kim
HKHoon-Gu Kim
Hoon-Gu Kim
GKGyung Hyuck Ko
Gyung Hyuck Ko
JLJong Sil Lee
Jong Sil Lee
The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-specific polymerase chain reaction to investigate MGMT promoter methylation status and immunohistochemistry to evaluate MGMT expression in patients with DLBCL who received rituximab plus CHOP (R-CHOP) chemotherapy. No difference in patient characteristics, disease characteristics, response, or survival in patients with DLBCL who received front-line R-CHOP chemotherapy was observed according to MGMT methylation status and MGMT expression. On multivariate analysis, Grade 3–4 mucositis in the MGMT methylated group was significantly higher than that in the MGMT unmethylated group (hazard ratio (HR) 2.40, 95% CIs: 1.26–7.26, p = 0.014). This study demonstrated that inactivation of MGMT does not appear to play an important role in patients with DLBCL who received R-CHOP chemotherapy either with regard to the response rate or overall survival. Additionally, Grade 3–4 mucositis was found to be significantly related with inactivation of MGMT by a multivariate analysis.

9 June 2012
Verified
Journal Article
Closed access
SGSe-Il Go
Se-Il Go
WLWon Sup Lee
Won Sup Lee
MKMyung Hee Kang
Myung Hee Kang
HSHaa-Na Song
Haa-Na Song
MKMoon Jin Kim
Moon Jin Kim
GKGyung Hyuck Ko
Gyung Hyuck Ko

1 December 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDavid Hui
David Hui
MKMeghan Sri Karuturi
Meghan Sri Karuturi
KTKimberson C. Tanco
Kimberson C. Tanco
JKJung Hye Kwon
Jung Hye Kwon
SKSun Hyun Kim
Sun Hyun Kim
Eduardo BrueraEduardo Bruera
Eduardo Bruera
215 Background: Chemotherapy use at the end of life is considered an indicator of poor quality of care. The use of targeted agent has not been well characterized. In this study, we determined the frequency and predictors of targeted therapy use in the last 30 days of life. Methods: All adult patients residing in the Houston area who died of advanced cancer between September 1, 2009 and February 28, 2010 and had contact with our institution within the last three months of life were included. We collected baseline demographics and data on chemotherapy and targeted agents. Results: 816 patients were included: average age 62 (range 21 to 97), female 48% and White 61%. The median interval between the last treatment and death was 47 (interquartile range 21 to 97) days for targeted agents and 57 (26 to 118) days for chemotherapeutic agents. 116 (14%) patients received targeted agents and 147 (18%) received chemotherapy within the last 30 days of life. 43 (5%) patients received targeted agents had concurrent chemotherapy. The most common targeted agents in the last 30 days of life were erlotinib (n=25), bevacizumab (n=20) and rituximab (n=11). In multivariate analysis, younger age, hematologic, and lung malignancies were associated with increased targeted agent use in the last 30 days of life (Table). Conclusions: Targeted agents were used as often as chemotherapy at the end of life, particularly among younger patients and those with hematologic malignancies. Guidelines on targeted therapy use at the end of life are needed. [Table: see text]

1 December 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDavid Hui
David Hui
SKSun Hyun Kim
Sun Hyun Kim
JKJung Hye Kwon
Jung Hye Kwon
KTKimberson C. Tanco
Kimberson C. Tanco
TZTao Zhang
Tao Zhang
Eduardo BrueraEduardo Bruera
Eduardo Bruera
25 Background: Palliative care (PC) access is a critical component of quality cancer care. Previous studies on PC access have mostly examined the timing of PC referral. The proportion of patients who actually received PC is unclear. We determined the proportion of cancer patients who received PC at our comprehensive cancer center, and the predictors of PC referral. Methods: We reviewed the charts ofconsecutive patients with advanced cancer from the Houston region seen at MD Anderson Cancer Center and died between September 2009 and February 2010. We compared patients who received PC services with those who did not receive PC services before death using univariate and multivariate logistic regression. Results: A total of 366/816 (45%) decedents had a PC consultation. The median interval between PC consultation and death was 1.4 months (interquartile range (0.5-4.2) and the median number of medical team encounters before PC was 20 (6-45). In multivariate analysis, older age, being married, and specific cancer types (gynecology, lung and head and neck) were significantly associated with a PC referral (Table). Patients with hematologic malignancies had significantly fewer PC referrals (33%), the longest interval between advanced cancer diagnosis and PC consultation (median 16 months), the shortest interval between PC consultation and death (median 0.4 month), and one of the largest number of medical team encounters (median 38) before PC. Conclusions: We found that a majority of cancer patients at our cancer center did not access PC before they die. PC referral occurs late in the disease process with many missed opportunities for referral. Further effort is needed to improve quality of end-of-life care. [Table: see text]

1 December 2015
Verified
Journal Article
Closed access
JSJin Ho Song
Jin Ho Song
BJBae-Kwon Jeong
Bae-Kwon Jeong
HCHoon-Sik Choi
Hoon-Sik Choi
HJHojin Jeong
Hojin Jeong
MKMyoung Hee Kang
Myoung Hee Kang
KKKi Mun Kang
Ki Mun Kang